Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals reported Q2 2026 net revenue of $74.3 million, an 88% increase year-over-year, driven by approximately 325,000 VOQUEZNA prescriptions filled during the quarter. The company achieved operating profitability excluding stock-based compensation for the first time, with operating expenses decreasing 33% year-over-year to $63.1 million.
Key figures
- Revenue
- 74300000
- Guidance
- FY2026 Net Revenue $310-325 million (updated from $320-345 million); Non-GAAP OpEx $235-245 million
- Revenue Yoy
- 88%
- Gaap net loss
- 17600000
- Operating expenses
- 63100000
- Cash and equivalents
- 182500000
- Prescriptions filled q2
- 325000
- Covered prescriptions q2
- 209000
- Prescriptions filled total
- 1700000
- Operating expenses yoy change
- -33%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.